Eli Lilly issues corrected release on AAIC 2026 Alzheimer’s research presentations

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly issued a corrected version of its July 9 release on planned AAIC 2026 Alzheimer’s research presentations.
  • The amended release adds detail on Kisunla analyses from TRAILBLAZER-ALZ 6 and the TRAILBLAZER-ALZ 2 long-term extension, including modified titration and corticosteroid pretreatment safety data.
  • It also clarifies new P-tau217 blood-test results, citing rule-in performance comparable to amyloid PET in cognitively unimpaired individuals.
  • The corrected schedule highlights 16 AAIC 2026 abstracts, including three oral presentations spanning donanemab, diagnostics, and trial methodology.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.